Cigna Assurance Rx: $0 copay for Tier 1 drugs from preferred retail pharmacies and preferred mail-order pharmacies (as a 90-day supply). Cigna Extra Rx: $0 copay for 90-day supplies of Tier 1 ...

The FDA in February formally declared the end of the semaglutide shortage, which Novo Nordisk expects will help improve the ...

Novo Nordisk now expects sales to grow 13% to 21% in constant currencies this year, from 16% to 24% previously. Operating profit should grow 16% to 24% compared with a previous target of 19% to 27%.

Novo Nordisk’s oral Wegovy pill for chronic weight loss is under FDA review. If approved, it would be the first oral GLP-1 ...

Novo Nordisk scored ... in those drugs, semaglutide, is no longer in shortage in the U.S. Patients flocked to the cheaper copycats when Ozempic and Wegovy were in short supply over the last ...

70. Novo Nordisk has notched a major legal win against compounding pharmacies that make copies of its diabetes and obesity drug semaglutide, sold under the brand names Ozempic and Wegovy.

"It's amazing how that'll solve like 90% of the problems, because the drivers are the interface between the radio and the operating system, and they can get discombobulated," Coleman says.

Novo Nordisk also markets Rybelsus ... a 90-day pause on all trading partners, excluding China, when imposed, tariffs on pharmaceutical imports can lead to potential disruptions to global supply ...

Read my honest 90-day Aqua Sculpt review - explore how this natural supplement works, its unexpected benefits, real results, ingredients, and if it's worth trying for weight loss and wellness.

Novo Nordisk (NYSE: NVO), the Danish drugmaker ... that helped the stock dodge the market downturn entirely and end the day somewhat in the green. The same news that helped Novo stock out ...